Earlier this year, the FDA approved 2 new indications for Aquaflor. According to Merck, the supplemental approval increased ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck’s Animal health and vaccine products are core growth drivers. It has a strong cancer pipeline, including Keytruda.

Various veterinary businesses and organizations recently announced new promotions and appointments. The following individuals ...

Despite challenges in GARDASIL sales, Merck & Co Inc (MRK) reports robust growth in KEYTRUDA and new product launches, ...

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...

Dow has been struggling to grow for several quarters. Keytruda now makes up close to half of Merck's revenue. As you can see ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

Merck & Co., Inc.'s Q3 earnings report is anticipated ... falling owing to the patent expirations of Januvia and Janumet. Animal Health revenues also fell by ~2%. Despite the approval of Winrevair ...